ImmunoGen, Inc. (NASDAQ:IMGN) Rating Increased to Hold at ValuEngine

Judith Bessette
Julho 12, 2017

They now have a United States dollars 6 price target on the stock.

According to Zacks, "ImmunoGen has made significant progress with regard to its lead pipeline candidate, mirvetuximab soravtansine (platinum-resistant ovarian cancer)". Hedge funds and other institutional investors own 73.93% of the company's stock. Moreover, ImmunoGen has only a limited number of wholly owned candidates in its pipeline. However, most of the pipeline candidates are in early stages of development and still a long way from entering the market, if at all. Hence successful development and subsequent approval of its lead candidate, is crucial for growth at ImmunoGen.

Several analysts have issued reports on IMGN shares. (NASDAQ:IMGN) in a report issued on Monday, June 26th.

Atlético de Madrid anuncia a contratação de Vitolo
No Sevilha desde 2013, proveniente do Las Palmas , Vitolo tem como principais troféus no currículo as três edições da Liga Europa, em 2014, 2015 e 2016.

Recently analysts working for various investment brokerages have changed their ratings and price targets on shares of ImmunoGen, Inc. Finally, Cantor Fitzgerald reissued a "hold" rating and issued a $5.00 target price on shares of ImmunoGen in a report on Wednesday, May 24th. Jefferies Group LLC reiterated a "buy" rating and set a $6.00 target price on shares of ImmunoGen in a research note on Wednesday, April 12th. Finally, Cowen and Company reaffirmed a hold rating on shares of ImmunoGen in a research report on Saturday, May 6th. The company has an average rating of Hold and a consensus target price of $6.76.

Immunogen Inc (NASDAQ:IMGN) has grabbed attention from the analysts, when it saw a value decrease of -4.79% or -0.37 points in the last trading session to close at $7.36. The company's stock had a trading volume of 1,995,253 shares. The stock's market capitalization is $669.22 million. The stock has a 50 day moving average of $5.12 and a 200 day moving average of $3.52. ImmunoGen has a one year low of $1.51 and a one year high of $8.04.

ImmunoGen (NASDAQ:IMGN) last posted its quarterly earnings results on Friday, May 5th. The company beat the analyst EPS Estimate with the difference of $-0.12. The company had revenue of $28.70 million for the quarter, compared to analysts' expectations of $16.16 million. During the same quarter in the previous year, the business earned ($0.37) EPS. The business's revenue for the quarter was up 45.7% compared to the same quarter past year. Equities research analysts forecast that ImmunoGen will post ($1.30) EPS for the current year. ImmunoGen, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Goldberg Mark Alan has acquired 20,000 shares of ImmunoGen, Inc. "(NASDAQ:IMGN) Rating Increased to Hold at ValuEngine" was reported by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another site, it was copied illegally and reposted in violation of US & global copyright and trademark laws. The original version of this article can be accessed at Norges Bank purchased a new stake in ImmunoGen during the fourth quarter valued at $3,123,000. Acadian Asset Management LLC purchased a new position in shares of ImmunoGen during the first quarter worth approximately $117,000. Clearbridge Investments LLC now owns 14,428,856 shares of the biotechnology company's stock valued at $55,840,000 after buying an additional 884,524 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of ImmunoGen by 2.8% in the first quarter. Bank of America Corp DE increased its stake in shares of ImmunoGen by 10.5% in the first quarter. Neuberger Berman Group LLC now owns 47,943 shares of the biotechnology company's stock valued at $186,000 after buying an additional 3,616 shares during the period.

Outros relatórios LazerEsportes

Discuta este artigo